Literature DB >> 29228504

Dynamic borrowing through empirical power priors that control type I error.

Stavros Nikolakopoulos1, Ingeborg van der Tweel1, Kit C B Roes1.   

Abstract

In order for historical data to be considered for inclusion in the design and analysis of clinical trials, prospective rules are essential. Incorporation of historical data may be of particular interest in the case of small populations where available data is scarce and heterogeneity is not as well understood, and thus conventional methods for evidence synthesis might fall short. The concept of power priors can be particularly useful for borrowing evidence from a single historical study. Power priors employ a parameter <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>γ</mml:mi> <mml:mo>∈</mml:mo> <mml:mo>[</mml:mo> <mml:mn>0</mml:mn> <mml:mo>,</mml:mo> <mml:mn>1</mml:mn> <mml:mo>]</mml:mo></mml:math> that quantifies the heterogeneity between the historical study and the new study. However, the possibility of borrowing data from a historical trial will usually be associated with an inflation of the type I error. We suggest a new, simple method of estimating the power parameter suitable for the case when only one historical dataset is available. The method is based on predictive distributions and parameterized in such a way that the type I error can be controlled by calibrating to the degree of similarity between the new and historical data. The method is demonstrated for normal responses in a one or two group setting. Generalization to other models is straightforward.
© 2017, The International Biometric Society.

Entities:  

Keywords:  Clinical trials; Dynamic borrowing; Power priors; Type I error

Mesh:

Year:  2017        PMID: 29228504     DOI: 10.1111/biom.12835

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

Review 1.  Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges.

Authors:  Moreno Ursino; Nigel Stallard
Journal:  Int J Environ Res Public Health       Date:  2021-01-24       Impact factor: 3.390

2.  Applicability and added value of novel methods to improve drug development in rare diseases.

Authors:  Marian Mitroiu; Katrien Oude Rengerink; Caridad Pontes; Aranzazu Sancho; Roser Vives; Stella Pesiou; Juan Manuel Fontanet; Ferran Torres; Stavros Nikolakopoulos; Konstantinos Pateras; Gerd Rosenkranz; Martin Posch; Susanne Urach; Robin Ristl; Armin Koch; Spineli Loukia; Johanna H van der Lee; Kit C B Roes
Journal:  Orphanet J Rare Dis       Date:  2018-11-12       Impact factor: 4.123

3.  Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control.

Authors:  Annette Kopp-Schneider; Silvia Calderazzo; Manuel Wiesenfarth
Journal:  Biom J       Date:  2019-07-02       Impact factor: 2.207

4.  An adaptive power prior for sequential clinical trials - Application to bridging studies.

Authors:  Adrien Ollier; Satoshi Morita; Moreno Ursino; Sarah Zohar
Journal:  Stat Methods Med Res       Date:  2019-11-15       Impact factor: 3.021

5.  Handling Poor Accrual in Pediatric Trials: A Simulation Study Using a Bayesian Approach.

Authors:  Danila Azzolina; Giulia Lorenzoni; Silvia Bressan; Liviana Da Dalt; Ileana Baldi; Dario Gregori
Journal:  Int J Environ Res Public Health       Date:  2021-02-21       Impact factor: 3.390

6.  Summarising salient information on historical controls: A structured assessment of validity and comparability across studies.

Authors:  Anthony Hatswell; Nick Freemantle; Gianluca Baio; Emmanuel Lesaffre; Joost van Rosmalen
Journal:  Clin Trials       Date:  2020-09-21       Impact factor: 2.486

7.  Combined assessment of early and late-phase outcomes in orphan drug development.

Authors:  Konstantinos Pateras; Stavros Nikolakopoulos; Kit C B Roes
Journal:  Stat Med       Date:  2021-04-04       Impact factor: 2.373

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.